Search
Cyclophosphamide Treatment Options in Kansas
A collection of 186 research studies where Cyclophosphamide is the interventional treatment. These studies are located in the Kansas, United States. Cyclophosphamide is used for conditions such as Breast Cancer, Lymphoma and Leukemia.
37 - 48 of 186
Match to Clinical Trials
Access to cutting-edge treatments
Latest clinical trials
Find trials in your area
Search by Name
Filter by Condition
Filter by Age
Filter by Type
Gender
Type of Study
Clinical Trial Phase
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Featured Offer
Lose Weight with GLP-1 Medications
Recruiting
Policy Lab has partnered with OnlineSemaglutide.org to offer trusted access to semaglutide and other GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
Conditions:
Overweight
Overweight and Obesity
Obesity
Weight Loss
Morbid Obesity
A Study of PCI-32765 (Ibrutinib) in Combination With Either Bendamustine and Rituximab or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Participants With Previously Treated Indolent Non-Hodgkin Lymphoma
Completed
The purpose of this study is to evaluate the efficacy and safety of PCI-32765 (ibrutinib) administered in combination with either bendamustine and rituximab (BR) or rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in adult participants with previously treated indolent Non-Hodgkin lymphoma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/22/2025
Locations: Not set, Westwood, Kansas
Conditions: Lymphoma
Study to Compare Axicabtagene Ciloleucel With Standard of Care Therapy as First-line Treatment in Participants With High-risk Large B-cell Lymphoma
Recruiting
The goal of this clinical study is to compare the study drug, axicabtagene ciloleucel, versus standard of care (SOC) in first-line therapy in participants with high-risk large B-cell lymphoma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/16/2025
Locations: The University of Kansas Hospital, Westwood, Kansas
Conditions: High-risk Large B-cell Lymphoma (LBCL)
A Phase 2 Study of Firi-cel in Patients With Relapsed/Refractory Large B-cell Lymphoma
Terminated
This is a prospective, open-label, multi-center clinical study designed to evaluate the safety, tolerability, efficacy, pharmacokinetics, pharmacodynamics, and immunogenicity of firicabtagene autoleucel (firi-cel), a CD22-directed autologous Chimeric Antigen Receptor (CAR) T-cell therapy for the treatment of relapsed or refractory large B-cell lymphoma (LBCL).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/13/2025
Locations: University of Kansas Medical Center Research Institute, Inc, Westwood, Kansas
Conditions: Cancer, Relapsed/Refractory Large B-cell Lymphoma (LBCL)
S0016 Combination Chemotherapy With Monoclonal Antibody Therapy in Newly Diagnosed Non-Hodgkin's Lymphoma
Active Not Recruiting
RATIONALE: Drugs used in chemotherapy work in different ways to stop cancer cells from dividing so they stop growing or die. Monoclonal antibodies can locate tumor cells and either kill them or deliver radioactive tumor-killing substances to them without harming normal cells. It is not yet known which monoclonal antibody plus combination chemotherapy regimen is more effective in treating non-Hodgkin's lymphoma.
PURPOSE: This randomized phase III trial is comparing 2 different monoclonal antibod... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/12/2025
Locations: Cancer Center of Kansas, PA - Chanute, Chanute, Kansas +24 locations
Conditions: Lymphoma
Study of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Participants With Relapsed/Refractory Follicular Lymphoma
Active Not Recruiting
The goal of this clinical study is test how well the study drug, axicabtagene ciloleucel, works in participants with relapsed/refractory follicular lymphoma
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/07/2025
Locations: The University of Kansas Hospital, Westwood, Kansas
Conditions: Relapsed/Refractory Follicular Lymphoma
Combination Chemotherapy With or Without Radiation Therapy in Treating Young Patients With Newly Diagnosed Stage III or Stage IV Wilms' Tumor
Active Not Recruiting
This phase III trial is studying how well combination chemotherapy with or without radiation therapy works in treating young patients with newly diagnosed stage III or stage IV Wilms' tumor. Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high-energy x-rays to kill tumor cells. Giving more than one drug (combination chemotherapy) with or without radiation therapy may kill mo... Read More
Gender:
ALL
Ages:
29 years and below
Trial Updated:
04/30/2025
Locations: University of Kansas Cancer Center, Kansas City, Kansas
Conditions: Stage III Kidney Wilms Tumor, Stage IV Kidney Wilms Tumor
IDP-023 g-NK Cells Plus Ocrelizumab in Patients With Progressive Multiple Sclerosis
Suspended
This is an open label, Phase 1b, multiple ascending dose, and dose-expansion study of IDP-023 administered in combination with interleukin-2 (IL-2) and ocrelizumab to evaluate the safety, tolerability, and biologic activity on autoreactive immune cells in patients with refractory progressive multiple sclerosis.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
04/28/2025
Locations: Kansas University Medical Center, Kansas City, Kansas
Conditions: Multiple Sclerosis, Primary Progressive Multiple Sclerosis (PPMS), Secondary Progressive Multiple Sclerosis (SPMS), Non-Active Secondary Progressive Multiple Sclerosis, Non-Active SPMS, Autoimmune Diseases of the Nervous System, Nervous System Diseases, Autoimmune Diseases, Demyelinating Diseases, Immune System Diseases, Demyelinating Autoimmune Diseases, Central Nervous System (CNS)
A Study of JNJ-68284528 Out-of-Specification (OOS) for Commercial Release in Participants With Multiple Myeloma
Completed
The purpose of this study is to evaluate the efficacy and safety of cilta-cel out-of-specification (OOS).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/24/2025
Locations: Kansas University Medical Center, Westwood, Kansas
Conditions: Multiple Myeloma
DALY II USA/ MB-CART2019.1 for DLBCL
Recruiting
DALY II USA is a phase II, multi-center, single arm study to evaluate the efficacy, safety, and pharmacokinetics of zamtocabtagene autoleucel (MB-CART2019.1) in patients with relapsed and/or refractory diffuse large B cell lymphoma (DLBCL) after receiving at least two lines of therapy. Additional cohorts include subjects with B-cell primary or secondary central nervous system (CNS) lymphoma (PCNSL) and (SCNSL), mantle cell lymphoma (MCL) and Richter's transformation (RT) after receiving at least... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/21/2025
Locations: University of Kansas Cancer Center, Westwood, Kansas
Conditions: Refractory Diffuse Large B Cell Lymphoma (DLBCL), Relapsed Diffuse Large B Cell Lymphoma, High Grade B-cell Lymphoma (HGBCL), Primary Mediastinal B-cell Lymphoma (PMBCL), Transformed Lymphoma, Central Nervous System Lymphoma, Mantle Cell Lymphoma (MCL), Richter Transformation
Study Evaluating SC291 in Subjects With r/r B-cell Malignancies (ARDENT)
Active Not Recruiting
SC291-101 is a Phase 1 study to evaluate SC291 safety and tolerability, anti-tumor activity, cellular kinetics, immunogenicity, and exploratory biomarkers.
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
04/09/2025
Locations: University of Kansas Medical Center, Fairway, Kansas
Conditions: Non Hodgkin Lymphoma, Chronic Lymphocytic Leukemia
Study Evaluating SC262 in Subjects With r/r Non-Hodgkin's Lymphoma (VIVID)
Recruiting
SC262-101 is a Phase 1 study to evaluate SC262 safety and tolerability, anti-tumor activity, cellular kinetics, immunogenicity, and exploratory biomarkers.
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
04/09/2025
Locations: The University of Kansas Hospital, Kansas City, Kansas
Conditions: Non Hodgkin's Lymphoma, Large B-cell Lymphoma
Evaluating the Safety and Efficacy of DuoCAR20.19.22-D95 in Adult Patients With Relapsed or Refractory B-cell Malignancies
Recruiting
This multicenter phase 1 trial with "3 + 3" dose escalation design seeks to examine the feasibility and safety of the administration of autologous T cells that have been modified through the introduction of chimeric antigen receptors targeting the B cell surface antigens CD19/20/22 following administration of a chemotherapy lymphodepletion regimen in adults with relapsed/refractory B-cell acute lymphoblastic leukemia (ALL) or Non-Hodgkin's lymphoma (NHL). The overall goals of this study are to e... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/03/2025
Locations: University of Kansas Cancer Center, Westwood, Kansas
Conditions: B-Cell Non-Hodgkin Lymphoma, B-cell Acute Lymphoblastic Leukemia
37 - 48 of 186